共 272 条
[1]
Miwa M(1998)Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue Eur J Cancer 34 1274-1281
[2]
Ura M(2007)Intermittent capecitabine monotherapy with lower dose intensity in heavily pretreated patients with metastatic breast cancer Tumori 93 129-132
[3]
Nishida M(2004)Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer Eur J Cancer 40 536-542
[4]
Sawada N(2004)Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer Acta Oncol 43 186-189
[5]
Ishikawa T(1997)Patient preferences for oral versus intravenous palliative chemotherapy J Clin Oncol 15 110-115
[6]
Mori K(2002)Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer Eur J Cancer 38 349-358
[7]
Shimma N(2006)A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer Ann Oncol 17 239-245
[8]
Umeda I(2001)Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma Eur J Cancer 37 597-604
[9]
Ishitsuka H(2000)New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205-216
[10]
Osako T(1983)Multivariate analysis of prognostic factors in metastatic breast cancer J Clin Oncol 1 776-786